Genmab — Juli 2019
-
Tisotumab Vedotin innovaTV 204 Pivotal Trial Data Expected in 2020: Seattle Genetics and Genmab previously reported the completion of enrollment in the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Topline data from the trial are expected in the first half of 2020. [ from SGEN earnings ]
-
But wouldn't they look for a partner for TV?
-
@Plimsoller Seattle Genetics is their partner.
-
Sorry. You are of course right. Thank you.
-
Q2 2019 Johnson & Johnson Earnings Call Transcript https://finance.yahoo.com/news/edited-transcript-jnj-earnings-conference-122731356.html
-
Stock... ser ud til det sker i dag..:-)
-
Let me start with DARZALEX. I'm telling you that we are very pleased with the provision of DARZALEX. We had a very strong growth in the quarter with 57%, 41% when you neutralize for the onetime price effect. So we are pleased with the progression -- with operation of DARZALEX and the strong growth that we are having across all lines of therapy. Particularly, recently, we've had 2 important events.
-
One is the approval of the frontline indication in transplant-ineligible patients in the combination with REVLIMID, which was much anticipated, and that will give us, together with the filing of the also frontline indication in transplant eligible, will give us 3 indications in frontline.
-
So to your question on the duration. As we move into earlier lines, the duration of the treatment increases. When it comes to the subcu that we filed earlier this week, we think this is a very important opportunity for DARZALEX overall. Keep in mind that we're going to be able to reduce the infusion time from 8 hours that we have today to 5 minutes.
-
So that's going to give significant advantages in terms of adoption of DARZALEX, in particular in earlier lines and particularly when you think that 50% of the use of DARZALEX today in the U.S. is in oncology clinics in outpatient patients. So we think that this combination is going to make DARZALEX easier to use for physicians,
-
more convenient to patients, that if you add to that the number of studies in which we are showing very, very strong results in frontline, will portend for a very positive continue adoption of DARZALEX that we see one of the major drivers of the growth of the pharmaceutical group. [end quote]
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind